Berlin, 28.02.2020– Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that the Centers for Medicare & Medicaid Services (CMS) have opened the National Coverage Determination (NCD) review of Epi proColon, Epigenomics’ blood test for colorectal cancer screening. This means that according to the statutes, a decision on CMS’s reimbursement of Epi proColon must be made within a maximum period of nine months. A positive CMS reimbursement decision would represent a major breakthrough for the company in the commercialization of Epi proColon in the U.S. market.
Epigenomics AG, Geneststraße 5, 10829 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, e-mail: email@example.com
IR.on AG, Frederic Hilke, Fabian Kirchmann, Tel +49 221 9140 970, e-mail: firstname.lastname@example.org